Organs and Body-on-Chip Translation to Human

The current drug discovery and development process is slow, costly, and risk-laden. It involves in vitro cell culture experiments and testing in animas. Extrapolation of drug effects from such preclinical studies to human is extremely challenging. Recently developed of Organ-on-Chip (OoC) and Human-on-Chip (HoC) experimental platforms are the disruptive technology in the drug development process. CFD Research, in collaboration with Wyss Inst. at Harvard Univ. under joint project with DAPA and with Los Alamos Labs have adapted CoBi tools for first principles-based simulations of OoC devices and HoC Micro physiological systems (MPS) [1,2,3].

CoBi tools have been used for modeling drug delivery, transport, absorption, metabolism and adverse effects in advanced microfluidic OoC devices. Unlike conventional lumped parameter models CoBi models represent the geometry, anatomy, physics and physiology of organ barriers using first principle-based models. The same models are used to simulate human in vivo barriers. This approach is being established as a next generation In Vitro to In Vivo Translation (IVIVT) framework, shown below.